71 P - Immune profile in chronic lymphocytic leukemia

Abstract

Immune profile in 29 cases with chronic lymphocytic leukemia (CLL) and I case with Richter's Syndrome was evaluated and compared with other prognostic parameters including disease stage, organomegaly, hematocrit, WBC count, platelet, bone marrow Involvement pattern, serum albumin and globulin profile and response to therapy. Monoclonal antibody panel included CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD13, CD14, CD19, CD20, CD22, CD23 and CD33. Surface antigenic expressions were as follows: CD2; in 5 of 16 cases (31%), CD3; in 2 of 23 cases (9%), CD4; in 2 of l6 cases (13%), CD5; in 24 of 27 cases (89%), CD7; in 11 of 26 cases (42%), CD8; in 1 of 17 cases (6%), CDl0; in 1 of 24 cases (4%-who was the case of Richter's Syndrome), CD11b; in none of the 11 cases, CD13; in 10 of 19 cases (53%) CD14; in none of 12 cases, CD19; in 27 of 29 cases (93%), CD20; in 5 of 15 cases (33%), CD22; in 5 of 8 cases (63%) and CD33; in 1 of 15 cases (6%). Between surface antigenic expressions, CD2 and CD7 expressions were associated with higher frequency of CD5 negativity as compared cases not expressing these antigens. When compared antigenic expressions and with other parometers, it bas been found that: CD2 expressions were associated wilh lower WBC Count, lower incidence of thrombocytopenia and splonemegaly and higher globulin value and higher incidence of thrombocytopenia and advanced stage disease. CD4 expression was associated with poorer response to therapy CD7 was associated with higher incidence of hepatomegaly, CD8 was associated with lower Hct value. CDl3 expression was associated with higher WBC count and more advanced stage disease. CD19 was associated with low risk of hepatomegaly, CD20 was assosiated with low risk of lymphadenopathy. CD22 was associated with lower incidence of hepatomegaly and well response to therapy.